Ultragenyx Pharmaceutical Inc.
Begin enrollment in the Phase 1/2/3 clinical study for UX701
Delivered after the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 21 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- October 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Enrollment in a seamless single-protocol Phase 1/2/3 study is expected to begin in the first half of 2021.”
What we found
Evidence strength A What the grades mean
The company announced in October 2021 that it had begun screening and enrolling patients for the UX701 study, which occurred after the first-half 2021 deadline.
-
A Ultragenyx Pharmaceutical Inc. 10-Q filed 2021-11-03
“In October 2021, we announced that we successfully screened and enrolled multiple patients with Wilson disease into the baseline monitoring period prior to dosing in the seamless Phase 1/2/3 study of UX701, the Cyprus2+ study.” ✓ confirmed on the page
Market reaction: the shares moved -3.2% against the S&P 500 over the three sessions around the disclosure (2 Nov 2021 to 5 Nov 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- UX701 Phase 1/2/3 clinical study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Ultragenyx Pharmaceutical Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-RARE-022264 · Corrections policy